Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

A Resized Recall Image cb1September 29 2017

A single batch of Xarelto 20mg film-coated tablets (rivaroxaban) is being recalled by Strathclyde Pharmaceuticals.

 The Class 2 alert issued by the MHRA affects batch number BXHHDR1, with expiry 09/2019, and pack size of 28 tablets. It was first distributed from September 18 2017.

The manufacturer “has received a report of a rogue blister strip of 15mg tablets within two packs of 20mg tablets and has decided to recall this batch. The labelling on one side of the blister strips reflects the correct strength of the tablets as shown in the diagrams,” said the MHRA.

Health professionals are being asked to identify any patients who may have had Xarelto 20mg dispensed since September 18 to check that they have the correct strength product. “If patients have been dispensed Strathclyde Pharmaceuticals Ltd Xarelto 20 mg tablets in compliance aids since 18 September 2017 inclusive, patients or carers should be asked to return the compliance aids to the pharmacy in order to be issued with replacements.”

Further information is available from Strathclyde Pharmaceuticals on 01355 574450 for medical enquiries and on 01355 574450 for stock enquiries.

Link:
MHRA recall announcement       

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...